批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/10/04 |
SUPPL-80(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/08/16 |
SUPPL-82(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/11/21 |
SUPPL-66(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/10/31 |
SUPPL-63(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2023/10/06 |
SUPPL-73(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/07/24 |
SUPPL-67(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2023/07/24 |
SUPPL-55(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/07/24 |
SUPPL-54(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2023/05/11 |
SUPPL-44(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2021/12/22 |
SUPPL-51(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2021/12/22 |
SUPPL-50(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2021/05/28 |
SUPPL-43(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2020/06/16 |
SUPPL-35(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2020/01/29 |
SUPPL-31(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2018/06/19 |
SUPPL-5(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2018/01/23 |
SUPPL-13(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2017/09/15 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/01/15 |
SUPPL-2(补充) |
Approval |
Efficacy |
|
|
|
2016/01/15 |
SUPPL-1(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2015/01/21 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:SECUKINUMAB 剂型/给药途径:INJECTABLE;INJECTION 规格:150MG/ML 治疗等效代码:TBD
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
125504 |
001 |
BLA |
COSENTYX |
SECUKINUMAB |
INJECTABLE;INJECTION |
150MG/ML |
Prescription |
TBD |
No |
TBD |
--
|
NOVARTIS PHARMS CORP |